DOC《临床研究组长》

电话:022-83865829-617. 公司简介 扶素生物技术有限公司成立于2002年,是中国领军的生物技术企业之一.基于计算机药物设计,公司致力于研发及产业化治疗重大病毒性疾病(例如艾滋病、乙肝、丙肝等)的专利药物. 基于对现有药物结构、药物靶点结构以及其相互作用的研究,扶素生物设计了活性高且安全性好的药物.这种模式可使扶素生物在更短的时间内以更低的研发费用设计出更优的药物. 扶素生物产品线中的主导项目为艾滋病病毒膜融合抑制剂西夫韦肽,正在开展临床试验. FusoGen Pharmaceuticals, Inc., founded in 2002, is a leading biotech company in China. The company is dedicated to the discovery, development, and commercialization of novel therapeutics against serious viral infections, such as HIV, hepatitis B, and hepatitis C, by the approach of computer drug design. Based on the structural knowledge of existing drugs, drug targets, and their interactions, FusoGen designs drugs with superior activity and reduced toxicity. We believe this model enables FusoGen to develop better drugs in shorter time and with much reduced R&D cost. The leading drug candidate in FusoGen's drug pipeline is Sifuvirtide, an HIV fusion inhibitor, which is currently undergoing Phase II clinical trial in China.